Barocci Simone, Orlandi Chiara, Diotallevi Aurora, Buffi Gloria, Ceccarelli Marcello, Vandini Daniela, Carlotti Eugenio, Galluzzi Luca, Rocchi Marco Bruno Luigi, Magnani Mauro, Casabianca Anna
Department of Clinical Pathology, Azienda Sanitaria Unica Regionale Marche Area Vasta 1 (ASUR Marche AV1), 61029 Urbino, PU, Italy.
Department of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, PU, Italy.
Vaccines (Basel). 2022 Mar 23;10(4):491. doi: 10.3390/vaccines10040491.
We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples were collected two months after vaccination from a total of 1248 subjects. The results showed that the heterologous vaccine schedule induced a significantly higher humoral response followed by homologous BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S vaccines (p < 0.0001). Moreover, analyzing factors (i.e., vaccine schedule, sex, age, BMI, smoking, diabetes, cardiovascular diseases, respiratory tract diseases, COVID-19 diagnosis, vaccine side effects) influencing the IgG anti-S response, we found that only the type of vaccine affected the antibody titer (p < 0.0001). Only mild vaccine reactions resolved within few days (40% of subjects) and no severe side effects for either homologous groups or the heterologous group were reported. Our data support the use of heterologous vaccination as an effective and safe alternative to increase humoral immunity against COVID-19.
我们评估了三个真实世界队列接种疫苗后的体液免疫反应。将接种ChAdOx1-S进行初次免疫并使用BNT162b2 mRNA疫苗进行加强免疫的受试者与同源接种方案（BNT162b2/BNT162b2和ChAdOx1-S/ChAdOx1-S）的受试者进行了比较。在接种疫苗两个月后，从总共1248名受试者中采集了血清样本。结果显示，与同源的BNT162b2/BNT162b2和ChAdOx1-S/ChAdOx1-S疫苗相比，异源疫苗接种方案诱导了显著更高的体液免疫反应（p < 0.0001）。此外，在分析影响IgG抗S反应的因素（即疫苗接种方案、性别、年龄、体重指数、吸烟、糖尿病、心血管疾病、呼吸道疾病、新冠病毒疾病诊断、疫苗副作用）时，我们发现只有疫苗类型影响抗体滴度（p < 0.0001）。只有少数轻微的疫苗反应在几天内得到缓解（40%的受试者），同源组和异源组均未报告严重副作用。我们的数据支持使用异源疫苗接种作为一种有效且安全的替代方案，以增强针对新冠病毒的体液免疫。
